1.645 USD
0 (-0.3%)
We assign a fundamental rating of 2 out of 10 to PRQR. PRQR was compared to 525 industry peers in the Biotechnology industry. Both the profitability and financial health of PRQR have multiple concerns. While showing a medium growth rate, PRQR is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year PRQR has reported negative net income.
- PRQR had a negative operating cash flow in the past year.
- In the past 5 years PRQR always reported negative net income.
- PRQR had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -34.23%, PRQR is in the better half of the industry, outperforming 63.05% of the companies in the same industry.
- PRQR has a Return On Equity (-74.59%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.23% | ||
| ROE | -74.59% | ||
| ROIC | N/A |
ROA(3y)-24.98%
ROA(5y)-30.3%
ROE(3y)-66.23%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for PRQR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- PRQR does not have a ROIC to compare to the WACC, probably because it is not profitable.
- PRQR has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for PRQR has been increased compared to 5 years ago.
- Compared to 1 year ago, PRQR has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -4.13, we must say that PRQR is in the distress zone and has some risk of bankruptcy.
- PRQR has a Altman-Z score of -4.13. This is comparable to the rest of the industry: PRQR outperforms 42.48% of its industry peers.
- A Debt/Equity ratio of 0.18 indicates that PRQR is not too dependend on debt financing.
- PRQR's Debt to Equity ratio of 0.18 is on the low side compared to the rest of the industry. PRQR is outperformed by 64.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.13 |
ROIC/WACCN/A
WACC7.04%
2.3 Liquidity
- A Current Ratio of 3.36 indicates that PRQR has no problem at all paying its short term obligations.
- PRQR has a Current ratio of 3.36. This is comparable to the rest of the industry: PRQR outperforms 40.38% of its industry peers.
- PRQR has a Quick Ratio of 3.36. This indicates that PRQR is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 3.36, PRQR perfoms like the industry average, outperforming 43.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.36 | ||
| Quick Ratio | 3.36 |
3. Growth
3.1 Past
- PRQR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -42.62%.
- The Revenue for PRQR has decreased by -24.60% in the past year. This is quite bad
- The Revenue has been growing by 58.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-42.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-24.6%
Revenue growth 3Y101.19%
Revenue growth 5Y58.89%
Sales Q2Q%-25.01%
3.2 Future
- Based on estimates for the next years, PRQR will show a very negative growth in Earnings Per Share. The EPS will decrease by -23.97% on average per year.
- Based on estimates for the next years, PRQR will show a very strong growth in Revenue. The Revenue will grow by 36.26% on average per year.
EPS Next Y-39.17%
EPS Next 2Y-33.29%
EPS Next 3Y-23.97%
EPS Next 5YN/A
Revenue Next Year-24.87%
Revenue Next 2Y-5.67%
Revenue Next 3Y-13.92%
Revenue Next 5Y36.26%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for PRQR. In the last year negative earnings were reported.
- Also next year PRQR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- PRQR's earnings are expected to decrease with -23.97% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.29%
EPS Next 3Y-23.97%
5. Dividend
5.1 Amount
- PRQR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:PRQR (1/20/2026, 9:48:39 AM)
1.645
0 (-0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-11 2026-03-11/amc
Inst Owners36.54%
Inst Owner Change1.81%
Ins Owners2%
Ins Owner ChangeN/A
Market Cap173.30M
Revenue(TTM)16.07M
Net Income(TTM)-42.57M
Analysts85.33
Price Target9.82 (496.96%)
Short Float %1.45%
Short Ratio2.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.4%
Min EPS beat(2)-43.58%
Max EPS beat(2)4.77%
EPS beat(4)2
Avg EPS beat(4)-11.12%
Min EPS beat(4)-43.58%
Max EPS beat(4)4.77%
EPS beat(8)5
Avg EPS beat(8)-84.26%
EPS beat(12)9
Avg EPS beat(12)-51.87%
EPS beat(16)11
Avg EPS beat(16)-43.54%
Revenue beat(2)0
Avg Revenue beat(2)-25.59%
Min Revenue beat(2)-35.24%
Max Revenue beat(2)-15.94%
Revenue beat(4)0
Avg Revenue beat(4)-20.41%
Min Revenue beat(4)-35.24%
Max Revenue beat(4)-2.1%
Revenue beat(8)1
Avg Revenue beat(8)-26.65%
Revenue beat(12)2
Avg Revenue beat(12)-24.13%
Revenue beat(16)6
Avg Revenue beat(16)-7.08%
PT rev (1m)0%
PT rev (3m)6.94%
EPS NQ rev (1m)6.37%
EPS NQ rev (3m)9.86%
EPS NY rev (1m)-1.78%
EPS NY rev (3m)-3.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.65%
Revenue NY rev (1m)-1.1%
Revenue NY rev (3m)-9.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 9.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.61 | ||
| P/tB | 2.61 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS0.18
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -34.23% | ||
| ROE | -74.59% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-24.98%
ROA(5y)-30.3%
ROE(3y)-66.23%
ROE(5y)-66.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 23.27% | ||
| Cap/Sales | 3.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.36 | ||
| Quick Ratio | 3.36 | ||
| Altman-Z | -4.13 |
F-Score2
WACC7.04%
ROIC/WACCN/A
Cap/Depr(3y)44.7%
Cap/Depr(5y)38.73%
Cap/Sales(3y)12.15%
Cap/Sales(5y)13.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-39.17%
EPS Next 2Y-33.29%
EPS Next 3Y-23.97%
EPS Next 5YN/A
Revenue 1Y (TTM)-24.6%
Revenue growth 3Y101.19%
Revenue growth 5Y58.89%
Sales Q2Q%-25.01%
Revenue Next Year-24.87%
Revenue Next 2Y-5.67%
Revenue Next 3Y-13.92%
Revenue Next 5Y36.26%
EBIT growth 1Y-66.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.5%
EBIT Next 3Y-16.57%
EBIT Next 5YN/A
FCF growth 1Y-696.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-639.62%
OCF growth 3YN/A
OCF growth 5YN/A
PROQR THERAPEUTICS NV / PRQR FAQ
What is the ChartMill fundamental rating of PROQR THERAPEUTICS NV (PRQR) stock?
ChartMill assigns a fundamental rating of 2 / 10 to PRQR.
Can you provide the valuation status for PROQR THERAPEUTICS NV?
ChartMill assigns a valuation rating of 0 / 10 to PROQR THERAPEUTICS NV (PRQR). This can be considered as Overvalued.
What is the profitability of PRQR stock?
PROQR THERAPEUTICS NV (PRQR) has a profitability rating of 1 / 10.
What is the financial health of PROQR THERAPEUTICS NV (PRQR) stock?
The financial health rating of PROQR THERAPEUTICS NV (PRQR) is 3 / 10.
What is the expected EPS growth for PROQR THERAPEUTICS NV (PRQR) stock?
The Earnings per Share (EPS) of PROQR THERAPEUTICS NV (PRQR) is expected to decline by -39.17% in the next year.